CD371 CAR IL18 T cell therapy (Memorial Sloan Kettering Cancer Center/Takeda)

N/A

Report date: 2025/07/30 20:01:17

Base Information

Drug NameCD371 CAR IL18 T cell therapy (Memorial Sloan Kettering Cancer Center/Takeda)
Drug Alias NameCLEc12a (CD371) Targeted ArmoRed Immune Effector Cells therapyCD371-specific/YSNVz/IL-18 CAR T cells therapyCD371-SAVVYz-IL18 Car T cell therapyCD371-YSNVZIL-18 CAR T CellsCD371-YSNVZ-IL18 CAR T cells therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionC-Type lectin domain family 12 member A modulatorsT lymphocyte replacementsImmunologic cytotoxicity
TargetsC-Type lectin domain family 12 member A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTakeda Development Center Americas IncMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A